DEF: Guardant Health Reports Strong 2024 Growth, Highlights FDA Approval of Shield

Guardant Health achieved significant milestones in 2024, including FDA approval of Shield and a 31% revenue increase, setting a positive trajectory for 2025.

Summary

• Guardant Health experienced substantial growth in 2024, marked by a 31% increase in revenue, reaching $739.0 million.
• The company delivered over 200,000 clinical tests during the year.
• A key achievement was the FDA approval and commercial launch of Shield, marking Guardant Health's entry into the blood-based early cancer detection market, starting with colorectal cancer.
• Therapy Selection tests showed strong momentum with record volume and revenue.
• The Guardant360 TissueNext test was upgraded with an expanded panel of biomarkers and improved turnaround time in June 2024.
• The Guardant 360 LDT was upgraded in July 2024, featuring a 9x expansion of reportable genes.
• The company continued its partnership with the Royal Marsden in the UK, where NHS England is testing non-small cell lung cancer patients using Guardant Health's liquid biopsy platform.
• A partnership with Policlinico Gemelli in Italy was established in September 2024 to create an in-house liquid biopsy test.
• Reveal was the fastest-growing product in the Minimal Residual Disease segment.
• The COSMOS study was published in August 2024, and a submission was made to Medicare for colorectal cancer surveillance reimbursement.
• Significant savings in Reveal cost per test were implemented, improving its financial profile.
• The Biopharma business accelerated, with over 180 cumulative partnerships by year-end.
• The pivotal ECLIPSE study was published in the New England Journal of Medicine in March 2024.
• Favorable Medicare pricing for Shield was obtained in November 2024.
• Progress was made towards the next version of Shield, aiming to improve colorectal cancer detection and detect multiple cancers at early stages.
• The company reported a net loss of $436.4 million for 2024, compared to $479.4 million in the previous year.
• Adjusted EBITDA loss was $257.5 million for 2024, compared to a $344.2 million loss in 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and key regulatory approvals, although tempered by ongoing losses. The tone is optimistic and forward-looking.

Positives

• Significant revenue growth of 31% year-over-year.
• FDA approval and commercial launch of Shield.
• Strong momentum in Therapy Selection with record volume and revenue.
• Successful partnerships with Royal Marsden and Policlinico Gemelli.
• Cost savings in Reveal, improving its financial profile.
• Acceleration in Biopharma business with continued traction.
• Favorable Medicare pricing for Shield.

Negatives

• Net loss of $436.4 million for 2024, although improved from $479.4 million in the previous year.
• Adjusted EBITDA loss of $257.5 million, although improved from $344.2 million in 2023.

Risks

• Continued losses may impact the company's ability to fund future growth.
• The success of Shield depends on commercial team execution and physician engagement.
• Future performance is subject to risks and uncertainties described in the company's filings.

Future Outlook

The company is set up favorably for 2025 and beyond, with sales momentum across the business and multiple new product introductions.

Management Comments

• 2024 was a very strong year of business execution consistent with our long-term strategy with sales momentum across the business and multiple new product introductions setting the company up favorably for 2025 and beyond.

Industry Context

Guardant Health is a leading precision oncology company, competing in the rapidly evolving liquid biopsy and early cancer detection markets. The FDA approval of Shield positions them as a frontrunner in blood-based colorectal cancer screening.

Comparison to Industry Standards

• Exact Sciences, another key player in colorectal cancer screening, offers Cologuard, a stool-based DNA test.
• Guardant Health's Shield competes directly with Cologuard and other non-invasive screening methods.
• Other companies like Freenome and Grail are developing multi-cancer early detection (MCED) tests, a market Guardant Health aims to enter with future versions of Shield.
• The 31% revenue growth is strong compared to the overall diagnostics industry, but specific competitor growth rates would provide a more precise benchmark.

Stakeholder Impact

• Shareholders: Potential for increased stock value due to revenue growth and product approvals.
• Patients: Access to innovative cancer screening and therapy selection tests.
• Employees: Opportunities for growth and development within a growing company.
• Biopharma Partners: Collaboration opportunities for drug development and clinical studies.

Next Steps

• Continue commercial rollout of Shield.
• Develop the next version of Shield to improve colorectal cancer detection.
• Advance the vision to have a blood test that can detect multiple cancers at early stages.

Key Dates

Keywords

Guardant Health, Shield, Liquid Biopsy, Cancer Screening, FDA Approval, Revenue Growth, EBITDA, Biopharma, Oncology, Medicare